Who is sponsoring NCT01048086?

NCT01048086 is sponsored by University of Iowa.

What condition does NCT01048086 study?

NCT01048086 studies Neuroblastoma, Neuroendocrine Tumor.

What drugs are being tested in NCT01048086?

Interventions: Retinoic Acid, Placebo.

What is the status of NCT01048086?

NCT01048086 is currently WITHDRAWN.

Last reviewed 2016-06-17 · How we verify

90Y-DOTA-tyr3-Octreotide With or Without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults. A Randomized, Placebo Controlled Phase II Trial With Dosimetry Guided Dosing

NCT01048086 Phase 2 WITHDRAWN

This study is for patients with neuroblastoma or a neuroendocrine tumor who have not been able to have standard therapy or have failed the first-line therapy. The purpose of this study is to assess the safety and effectiveness of the combination of retinoic acid and Onalta (Y-90-DOTA-tyr3-Octreotide) in treating neuroblastoma and neuroendocrine tumors.

Details

Lead sponsor	University of Iowa
Phase	Phase 2
Status	WITHDRAWN
Start date	2009-06
Completion	2013-11

Conditions

Neuroblastoma
Neuroendocrine Tumor

Interventions

Retinoic Acid
Placebo

Primary outcomes

Evaluate tumor response to 90Y-DOTA-tyr3-Octreotide alone and in combination with 13-cis retinoic acid for the treatment of children and young adults with recurrent, somatostatin-receptor positive tumors — 6 weeks after last treatment

Countries

United States